Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (91-100 of 199) with videos related to

Pageof 20
Sort By:
Journal of the National Cancer Institute|May 2, 2007
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyGrazia Arpino, Carolina Gutierrez, Heidi Weiss, et al.
Cancer|January 19, 2010
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, et al.
Advances in Experimental Medicine and Biology|January 17, 2025
HER2-Positive Breast Cancer Treatment and ResistanceJamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, et al.
Cancer Research|February 5, 2008
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionSuleiman Massarweh, C Kent Osborne, Chad J Creighton, et al.
Oncogene|April 13, 2005
Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutationsXiaomei Zhang, Katrina Podsypanina, Shixia Huang, et al.
Molecular Endocrinology (Baltimore, Md.)|November 25, 2005
Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen actionWilliam R Harrington, Sung Hoon Kim, Cory C Funk, et al.
Journal of Biophotonics|October 10, 2019
In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancerNrusingh C Biswal, Xiaoyong Fu, Jaidip M Jagtap, et al.
Breast Cancer Research and Treatment|March 17, 2006
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthJana Divisova, Isere Kuiatse, ZaWaunyka Lazard, et al.
Cancer Research|September 17, 2008
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton, Suleiman Massarweh, Shixia Huang, et al.
Molecular and Cellular Biology|June 3, 2010
Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cellsJaclyn S Long, Joanne Edwards, Carol Watson, et al.
Pageof 20

Showing results (91-100 of 199) with videos related to

Sort By:
Pageof 20
Journal of the National Cancer Institute|May 2, 2007
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyGrazia Arpino, Carolina Gutierrez, Heidi Weiss, et al.
Cancer|January 19, 2010
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, et al.
Advances in Experimental Medicine and Biology|January 17, 2025
HER2-Positive Breast Cancer Treatment and ResistanceJamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, et al.
Cancer Research|February 5, 2008
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionSuleiman Massarweh, C Kent Osborne, Chad J Creighton, et al.
Oncogene|April 13, 2005
Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutationsXiaomei Zhang, Katrina Podsypanina, Shixia Huang, et al.
Molecular Endocrinology (Baltimore, Md.)|November 25, 2005
Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen actionWilliam R Harrington, Sung Hoon Kim, Cory C Funk, et al.
Journal of Biophotonics|October 10, 2019
In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancerNrusingh C Biswal, Xiaoyong Fu, Jaidip M Jagtap, et al.
Breast Cancer Research and Treatment|March 17, 2006
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthJana Divisova, Isere Kuiatse, ZaWaunyka Lazard, et al.
Cancer Research|September 17, 2008
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton, Suleiman Massarweh, Shixia Huang, et al.
Molecular and Cellular Biology|June 3, 2010
Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cellsJaclyn S Long, Joanne Edwards, Carol Watson, et al.
Pageof 20